CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice : An NCDR Registry to Practice Project Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Late Survival Benefit of Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion: A 10-Year Follow-Up Study Optimum Blood Pressure in Patients With Shock After Acute Myocardial Infarction and Cardiac Arrest Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy A Novel Circulating MicroRNA for the Detection of Acute Myocarditis Association Between Collateral Circulation and Myocardial Viability Evaluated by Cardiac Magnetic Resonance Imaging in Patients With Coronary Artery Chronic Total Occlusion
|<<... 28 29 30 31 32 33 34 ...>>|

Original Research

JOURNAL：CBSMD Article Link

TAVR后的冠状动脉介入

CBSMD

Pre-reading


接受经导管主动脉瓣置换术(TAVR)治疗的患者的冠状动脉事件的累积风险较高，冠状动脉通路是否良好对于后续的冠脉介入是个挑战，最新一期的JACC Intervention为TAVR及后续的冠脉介入特刊

1. “Coronary Access After TAVR” 介绍了真实世界中通过CT明确的TAVR术后冠状动脉通路不良（unfavorable coronary access）患者的冠脉介入成功率数据后发现：

1）TAVR术后冠脉通路不良患者的冠脉介入成功率低于冠状动脉通路良好的患者。Evolut R/Evolut PRO 组(0.0% vs. 77.8%; p = 0.003)，SAPIEN 3 组(33.3% vs. 91.4%; p = 0.003) ；

2）提出了TAVR术中有助于保持良好冠状动脉通路的技术细节。


2. “Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography”介绍了通过多层计算机断层CT观察到的经导管心脏瓣膜（THV）中位TAVR 30天后与左、右冠脉开口的相对解剖位置。



3. Low Risk TAVR试验 "Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients"指出TAVR治疗会对低风险患者的冠状通路造成影响, 或引发主动脉瓣再干预（TAVR-in-TAVR）时的冠脉阻塞。



4. “Coronary Protection to Prevent Coronary Obstruction During TAVR：A Multicenter International Registry”则比较了TAVR术后冠脉保护的两种方案，3年随访结果显示:

1) 通过支架保护冠脉开口后的心源性死亡率显著低于导丝保护后的心源性死亡率（7.8% vs. 15.8%, adjusted hazard ratio: 0.42; 95% confidence interval: 0.14 to 1.28; p = 0.13）;且通过置入支架保护的TAVR患者的明确的支架内血栓发生率不高（0.9%）；

2）通过导丝保护冠脉开口的患者需要预防延迟性的冠脉闭塞（delayed coronary occlusions），发生率为4.3%。



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top